𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Platelet Inhibition in Percutaneous Coronary Interventions

✍ Scribed by Christophe A. Wyss; Marco Roffi

Publisher
Urban and Vogel
Year
2005
Tongue
German
Weight
446 KB
Volume
30
Category
Article
ISSN
0340-9937

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Platelet inhibition with tirofiban early
Platelet inhibition with tirofiban early during percutaneous coronary intervention: Dosing revisited
✍ Nasser Lakkis; Nada Lakiss; Jeremy Bobek; John Farmer πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 74 KB

## Abstract Platelet inhibition is central to the efficacy of the intravenous glycoprotein IIb/IIIa receptor inhibitors. Differences in the degree of platelet inhibition achieved with these agents may account for the disparity in clinical efficacy noted in recently completed clinical trials. The pu

Percutaneous coronary interventions in E
Percutaneous coronary interventions in Europe
✍ StΓ©phane Cook; Alexander Walker; Olivier HΓΌgli; Mario Togni; Bernhard Meier πŸ“‚ Article πŸ“… 2007 πŸ› Springer 🌐 English βš– 660 KB
Platelet receptor P2RY12 haplotypes pred
Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions
✍ Goran RudeΕΎ; Douwe Pons; Frank Leebeek; Pascalle Monraats; Marlies Schrevel; Aei πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 186 KB

The platelet receptor P2Y12 (gene symbol P2RY12) is involved in several processes that contribute to restenosis after percutaneous coronary interventions (PCI). Therefore, common variation in the P2Y12 gene may serve as a useful marker for risk stratification. We studied whether common variation in